Press releases
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
- Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
- Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
- Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
- Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
More ▼
Key statistics
On Friday, Everest Medicines Ltd (1952:HKG.HS) closed at 22.05, -31.52% below its 52-week high of 32.20, set on Nov 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.75 |
---|---|
High | 23.00 |
Low | 21.70 |
Bid | 22.05 |
Offer | 22.10 |
Previous close | 21.80 |
Average volume | 3.18m |
---|---|
Shares outstanding | 324.70m |
Free float | 194.05m |
P/E (TTM) | -- |
Market cap | 7.16bn HKD |
EPS (TTM) | -2.92 HKD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼